-
US Open under the influence: content creators spark debate
-
Raiders to start Cousins over top NFL Draft pick Mendoza
-
NBA hammers Clippers over Leonard salary cap violations
-
Palantir chief says France's digital sovereignty push 'backfiring'
-
NBA strips five first-round draft picks from Clippers for Leonard salary cap violations
-
US energy firms dominate Venezuela deals worth billions
-
Kane brace helps Bayern win German Cup opener
-
Iran, US trade threats after escalation in fighting
-
Migrant plight, local anger divide Ceuta one month after influx
-
US jury deadlocks again in Lindsay Clancy's child murder trial
-
Outrage as Maltese tycoon acquitted of reporter's murder
-
Lake America? No way, Canadians say
-
Rare train of Pacific cyclones fueled by historic El Nino
-
Spain report flags Moroccan police failings in Ceuta migrant rush
-
Macron, King Charles hail UK-France ties after viewing Bayeux Tapestry
-
Tech bosses press G20 to build data centers, but split on risk
-
Fury hits out at 'coward' Joshua as 'Battle of Britain' talks go on
-
Dolly Parton to get new Hollywood star after vandalism
-
Maltese tycoon acquitted of masterminding reporter's murder
-
Trump 'happy' Prince Harry and Meghan have left US
-
George Clooney: a Hollywood icon and campaigner
-
Michelson shocks Nakashima in US Open clash of rising Americans
-
Europe, US closer than they look on tech rules, says EU tech chief
-
Another body recovered after ferry capsizes off northern Cyprus: official
-
Clooney honoured as Hollywood-light Venice Film Festival kicks off
-
Cupertino Chamber President Claudio Bono Invited to White House with GiveaRoof 3-Year Plan to End Homelessness
-
Third-ranked Pegula, Medvedev power into US Open third round
-
Trump floats renaming Strait of Hormuz as 'Trump Strait'
-
Davis-Woodhall a doubt for Ultimate Championship after car crash
-
Man City, Chelsea fuel record-breaking Premier League transfer window
-
Third-ranked Pegula powers into US Open third round
-
Balogun rejected Everton move over transfer 'treatment'
-
Uber says laying off 'about 10%' of workforce worldwide
-
Northampton seek 'happy medium' in bid to keep England star Pollock
-
US judge rejects bid to break up Google's ad business
-
US energy secretary in Venezuela to sign Trump's 'biggest' oil deal
-
Rupert Murdoch 'very happy' to be played by Guy Pearce in new film
-
Branagh takes on action role in Apple's Cold War comedy 'Mayday'
-
Wall Street stocks rise despite bond yields, oil rising
-
Lawson fills in again for injured Hadjar at Monza
-
Brennan claims third Vuelta victory in stage 11 sprint
-
England omit Carse from squad for third Test against Pakistan
-
Nepal flood survivors cling to zipline to cross treacherous river
-
Venice festival gets underway with Clooney taking swipe at US government
-
US Treasury issues $1 coin with Trump's face on it
-
DNA tests and funerals in Nepal, a week after deadly floods
-
Fernandez 'didn't hesitate' over record Man City move
-
Iran threatens tougher strategy after US strikes kill 4 at wedding
-
Dutch shift 86 tonnes of gold from US, Canada to UK
-
Chevron unveils deal to double Venezuela venture output in 5 years
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report its first quarter 2025 financial results, and provide a corporate update.
A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.
Webcast: https://investors.modernatx.com
The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Media Contacts
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
[email protected]
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
O.Ortiz--AT